Invizyne Technologies INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
eXoZymes reported a wider 2025 net loss, sharply lower cash, and a going concern warning while advancing its NCT program and winning new grants.
eXoZymes Inc.'s 10-K filing provides a comprehensive overview of the company's capital stock, intellectual property, regulatory environment, and risk factors, highlighting its focus on biomanufacturing and its commercialization strategy.